Ansun Biopharma Enrolls First Patient in Trial of DAS181 for COVID-19
Ansun Biopharma announced the enrollment of the first patient in a proof-of-concept study to evaluate the safety and efficacy of DAS181, the Company's investigational recombinant sialidase for the treatment of severe COVID-19 infection. Read more...
BD Announces Second FDA Emergency Use Authorization, CE Mark for COVID-19 Molecular Diagnostic
BD announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for an additional molecular diagnostic test for COVID-19 that can return results in two to three hours. The new test also has been CE marked to the IVD Directive (98/79/EC). More news...
Xylyx Bio Offers Advanced Lung Models to Accelerate COVID-19-Related Drug Development
Xylyx Bio announced availability of products that recreate the lung environment in vitro to provide a predictive model that brings much-needed insight into the efficacy of COVID-19-related drug candidates. Read more...
AstraZeneca Initiates Calquence Clinical Trial against COVID-19
AstraZeneca will initiate a randomized, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients. Read more...
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.